Signet Financial Management LLC Grows Position in Invesco Biotechnology & Genome ETF $PBE

Signet Financial Management LLC increased its holdings in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 3.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,351 shares of the company’s stock after acquiring an additional 164 shares during the quarter. Signet Financial Management LLC owned approximately 0.13% of Invesco Biotechnology & Genome ETF worth $279,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PBE. Banque Cantonale Vaudoise purchased a new stake in Invesco Biotechnology & Genome ETF in the first quarter worth about $34,000. Millstone Evans Group LLC lifted its position in shares of Invesco Biotechnology & Genome ETF by 75.8% during the first quarter. Millstone Evans Group LLC now owns 1,684 shares of the company’s stock valued at $107,000 after buying an additional 726 shares during the last quarter. Beese Fulmer Investment Management Inc. purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the first quarter valued at about $216,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Invesco Biotechnology & Genome ETF by 33.1% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 3,808 shares of the company’s stock valued at $242,000 after buying an additional 948 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Invesco Biotechnology & Genome ETF by 10.6% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,066 shares of the company’s stock valued at $271,000 after buying an additional 390 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

PBE stock opened at $67.85 on Friday. The firm has a market cap of $234.08 million, a price-to-earnings ratio of 20.44 and a beta of 0.87. The firm has a 50-day simple moving average of $67.92 and a two-hundred day simple moving average of $64.65. Invesco Biotechnology & Genome ETF has a one year low of $54.52 and a one year high of $72.84.

Invesco Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.